Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Sinopharm Group Co., Ltd.    1099   CNE100000FN7

SINOPHARM GROUP CO., LTD.

(1099)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Factbox: COVID-19 vaccine frontrunners

11/09/2020 | 09:53am EST

(Reuters) - Pfizer and German partner BioNTech on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine, priming it for possible speedy regulatory approvals.

Moderna and AstraZeneca are close behind and are likely to have early data on their vaccine candidates before the end of the year. More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 42 in human trials, according to the World Health Organization (WHO).

(Reporting by Amruta Khandekar, Dania Nadeem, Mrinalika Roy and Vishwadha Chander in Bengaluru; editing by Ankur Banerjee, Maju Samuel, Ramakrishnan M. and Sriraj Kalluvila)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.86% 7963.7348 Delayed Quote.7.82%
BIONTECH SE 2.00% 110.61 Delayed Quote.35.68%
MODERNA, INC. 12.20% 147 Delayed Quote.40.71%
PFIZER INC. 2.00% 37.28 Delayed Quote.1.28%
SINOPHARM GROUP CO., LTD. 2.19% 19.56 End-of-day quote.3.71%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
All news about SINOPHARM GROUP CO., LTD.
01/25AstraZeneca's COVID-19 Vaccine Gains Approval in Bahrain
MT
01/25Hong Kong formally approves Fosun Pharma-BioNTech vaccine
RE
01/24MARKET CHATTER : WHO Mulls Granting Emergency Approvals to Two COVID-19 Vaccines..
MT
01/22WHO to consider two Chinese COVID-19 vaccines next week
RE
01/21India's vaccine diplomacy in south Asia pushes back against China
RE
01/21ANALYSIS : Surging cases strain UAE's open for business COVID strategy
RE
01/20World Health Organization Nears Emergency Approval for Three COVID-19 Vaccine..
MT
01/20SINOPHARM : Chinese COVID-19 Vaccine Makers Join WHO-backed COVAX Program
MT
01/20McKesson to replace some Moderna COVID-19 vaccines due to low temperature
RE
01/20WHO plans slew of COVID-19 vaccine approvals for global rollout
RE
More news
Financials
Sales 2020 459 B 70 976 M 70 976 M
Net income 2020 6 851 M 1 059 M 1 059 M
Net Debt 2020 15 485 M 2 393 M 2 393 M
P/E ratio 2020 7,30x
Yield 2020 4,09%
Capitalization 50 953 M 7 864 M 7 874 M
EV / Sales 2020 0,14x
EV / Sales 2021 0,13x
Nbr of Employees 93 764
Free-Float 43,0%
Chart SINOPHARM GROUP CO., LTD.
Duration : Period :
Sinopharm Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOPHARM GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 22,87 CNY
Last Close Price 16,35 CNY
Spread / Highest target 121%
Spread / Average Target 39,9%
Spread / Lowest Target 5,58%
EPS Revisions
Managers and Directors
NameTitle
Yong Liu President & Executive Director
Fang Yao Chairman-Supervisory Board
Qing Ming Yu Chairman
Xiu Chang Jiang Chief Financial Officer & Vice President
Jin Dong Deng Non-Executive Director
Sector and Competitors